However, our characterization of F1174S mutation has been carried out on the most commonly observed NSCLC EML4-ALK variants (1, 3a and 3b) and clearly demonstrates clinically relevant results that differ from EML4-ALK with F1174C/L/V mutations (13, 19, 34–36, 40). This evidence concerns the gene EML4 and non-small cell lung carcinoma.